Pharmaceutical composition, food or drink, and methods related thereto

a technology applied in the field of pharmaceutical composition and food or drink, can solve problems such as unfavorable side effects

Inactive Publication Date: 2010-12-30
MIYAZAKI TORU
View PDF1 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]However, there has been a problem in that an anti-obesity drug containing a low molecular compound which acts upon the cerebral nervous system as an active ingredient causes unfavorable side effects (such as anorexia).

Problems solved by technology

However, there has been a problem in that an anti-obesity drug containing a low molecular compound which acts upon the cerebral nervous system as an active ingredient causes unfavorable side effects (such as anorexia).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition, food or drink, and methods related thereto
  • Pharmaceutical composition, food or drink, and methods related thereto
  • Pharmaceutical composition, food or drink, and methods related thereto

Examples

Experimental program
Comparison scheme
Effect test

example 1

Expression of AIM by Macrophages in Adipose Tissue

[0221]A high fat diet (HFD, fat calorie 60%) was given to C57BL / 6 mice for 20 weeks. Likewise, HFD was also given to adiponectin-knockout mice (Adipo− / − mice) which were more obese. Subsequently, intraabdominal visceral adipose tissues were collected from those mice. Paraffin sections made from this adipose tissue were double-stained with an anti-macrophage monoclonal antibody (F4 / 80) and anti-mouse AIM polyclonal antibody (SA-1).

[0222]FIG. 4 shows an example of the results of observing the stained sections under a phase contrast microscope and a fluorescent microscope. In FIG. 4, photos under the phase contrast microscope (Phase), photos of stained macrophages under the fluorescent microscope (F4 / 80 macrophage), photos of stained AIM under the fluorescent microscope (AIM), and photos obtained by merging those fluorescence micrographs (merge) are shown for wild-type C57BL / 6 mice (Wild-type) and Adipo− / − mice (Adiponectin− / −).

[0223]As...

example 2

Inhibition of Differentiation of Adipocytes by AIM

[0224]In order to examine how AIM produced by the macrophages infiltrating the adipose tissues works on surrounding adipocytes, an experiment in which AIM was loaded during a culture process of differentiating 3T3-L1 preadipocytes into the mature adipocytes was performed.

[0225]That is, as illustrated in FIG. 5A, a culture of 3T3-L1 cells was performed in the following four mutually different schedules (a) to (d); (a) AIM was not loaded, (b) AIM was loaded for 10 days (day 2 to day 12) after the initiation of stimuli for differentiation induction, (c) AIM was loaded in a period of clonal expansion alone (day −2 to day 2) before the differentiation induction, and (d) AIM was loaded in the early phase alone (day 2 to day 4) of the stimuli for differentiation induction.

[0226]A recombinant mouse AIM protein and a recombinant human AIM protein were used as AIM. Those recombinant AIM proteins were prepared by culturing human-derived HEK293T...

example 31

Induction of Lipolysis by AIM

[0235]The effect of AIM on mature adipocytes was examined. As illustrated in FIG. 6A, as was the case with above Example 2, 3T3-L1 cells were cultured while loading mouse AIM for 6 days (day 6 to day 12) after the 3T3-L1 cells differentiated and lipid droplets were formed in the cells as a schedule (e).

[0236]Then, the cells on the 10th day (day 12) after the initiation of the stimuli for differentiation induction were stained with oil-red-o. The number of cells having lipid droplets was counted. Further, the diameter of lipid droplets was measured in the cells having lipid droplets. For comparison, the number of the cells was counted and the diameter of lipid droplets was measured for the cells cultured in the above-mentioned schedules (a) and (d).

[0237]Further, the supernatant of the culture medium after the cells were cultured while loading AIM according to the schedule (e) was collected, and amounts of glycerol and free fatty acid (FFA) contained in t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and/or a function of inducing lipolysis in the mature adipocytes.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]The present application claims priority from U.S. Provisional Patent Application No. 61 / 213, 349 filed on Jun. 1, 2009, the content of which is hereby incorporated by reference into this application.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to a pharmaceutical composition, food or drink, and methods related thereto.[0004]2. Description of the Related Art[0005]Various anti-obesity drugs are currently being developed. For example, an inhibitor of fatty acid synthase (FAS) has been reported to cause remarkable loss of appetite by reducing the amount of a neuropeptide Y (NPY) produced in the hypothalamus, resulting in decrease in body weight and fat amount (see, e.g., Loftus, T. M. et al. Science 288: 2379-2381 (2000)).SUMMARY OF THE INVENTION[0006]However, there has been a problem in that an anti-obesity drug containing a low molecular compound which acts upon the cerebral nervous system as ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/17C07K14/47A61P3/04
CPCA23L1/305C07K14/4703A61K38/00A23L2/66A23L33/17A61P3/04A61P43/00
Inventor MIYAZAKI, TORU
Owner MIYAZAKI TORU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap